Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst ...